Sort
17,828 grants matching “crispr”
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells
$369,780Krishanu Saha · University Of Wisconsin-Madison · R35 · FY2017 · GM
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells
$369,780Krishanu Saha · University Of Wisconsin-Madison · R35 · FY2020 · GM
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells
$369,780Krishanu Saha · University Of Wisconsin-Madison · R35 · FY2018 · GM
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells
$369,780Krishanu Saha · University Of Wisconsin-Madison · R35 · FY2019 · GM
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived Cells
$369,778Krishanu Saha · University Of Wisconsin-Madison · R35 · FY2016 · GM
Residual disease: unraveling immunosurveillance and immune evasion of disseminated tumor cells
$369,638Joan Massague · Sloan-Kettering Inst Can Research · U54 · FY2017 · CA
Project #2 - Banchereau
$369,615Maria Virginia Pascual · Weill Medical Coll Of Cornell Univ · P50 · FY2025 · AR
Trajectory and Architecture of Microenvironment-Mediated Resistance in AMLÂ
$369,603Anupriya Agarwal · Oregon Health & Science University · U54 · FY2022 · CA
Trajectory and Architecture of Tumor Intrinsic Drug Resistance in AML
$369,544Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2022 · CA
Investigating novel synthetic lethal epigenetic interactions in Acute Myeloid Leukemia
$369,504Junwei Shi · University Of Pennsylvania · R01 · FY2023 · CA
Understanding and exploiting the functional diversity of CRISPR-Cas immune systems
$369,490Chase Lawrence Beisel · North Carolina State University Raleigh · R35 · FY2020 · GM
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
$369,404Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer
$369,404Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Understanding and exploiting the functional diversity of CRISPR-Cas immune systems
$369,363Chase Lawrence Beisel · North Carolina State University Raleigh · R35 · FY2017 · GM
Targeting SUMO1 degradation for advanced colon cancer therapy
$369,353Anita Bellail · Indiana University Indianapolis · R01 · FY2022 · CA
Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS
$369,227Thomas Gaj · University Of Illinois At Urbana-Champaign · R01 · FY2022 · NS
Plexin-B2 function in glioma invasion and glioma stem cell maintenance
$369,219Roland Horst Friedel · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · NS
Plexin-B2 function in glioma invasion and glioma stem cell maintenance
$369,213Roland Horst Friedel · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · NS
Multiscale Modeling of Enzymatic Reactions and Bioimaging Probes
$369,028Yihan Shao · Brandeis University · R35 · FY2025 · GM
Investigating imitation SWI chromatin remodeling complexes in mammalian tissue regeneration
$369,000Hao Zhu · Ut Southwestern Medical Center · R01 · FY2022 · DK
Investigating imitation SWI chromatin remodeling complexes in mammalian tissue regeneration
$369,000Hao Zhu · Ut Southwestern Medical Center · R01 · FY2023 · DK
Elucidating Context-Specific FERONIA Receptor Kinase Signaling
$368,953Hongqing Guo · Iowa State University · R35 · FY2024 · GM
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis
$368,872Syreeta L Tilghman · Florida Agricultural And Mechanical Univ · SC1 · FY2020 · GM
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis
$368,872Syreeta L Tilghman · Florida Agricultural And Mechanical Univ · SC1 · FY2021 · GM
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis
$368,872Syreeta L Tilghman · Florida Agricultural And Mechanical Univ · SC1 · FY2019 · GM